Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Awaiting development
Process STA Standard
ID number 6327

Provisional Schedule

Expected publication 19 June 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Pfizer
Others Department of Health & Social Care
  NHS England
Patient carer groups Cardiomyopathy UK
  UK ATTR Amyloidosis Patients’ Association
Professional groups British Cardiovascular Society
  British Society for Heart Failure
  National Amyloidosis Centre
  Royal College of Physicians
  UK Clinical Pharmacy Association
Comparator companies Akcea Therapeutics UK (inotersen) - CAU not returned, not participating
  Alnylam Pharmaceuticals (patisiran,
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
13 May 2024 - 28 May 2024 Final draft guidance
03 April 2024 Committee meeting: 2
27 February 2024 - 19 March 2024 Draft guidance
06 February 2024 Committee meeting: 1
01 September 2023 Invitation to participate
01 September 2023 In progress. Invitation to Participate
18 August 2023 - 25 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 August 2023 Awaiting development

For further information on our processes and methods, please see our CHTE processes and methods manual